BCHE and myasthenia gravis: Type III dominated the Tac group (19/36, 53%), while type I appeared the most in the control group (15/34, 44%) and 53% (8/15) of these ocular MG patients required only single-agent therapy with cholinesterase inhibitors (Figure 2A).